LIVE

TYRA

Tyra Biosciences, Inc.

TYRA

NASDAQ·Healthcare·Biotechnology·Mkt cap $1.7B

$30.35

▲ +3.20%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$9.47 - $40.65

P/E

-13.92

Fwd P/E

-13.67

Beta

0.75

Div Yield

0.00%

Avg Vol

1.0M

Shares Out

53.7M

Mkt Cap

$1.7B

Price action

Price chart

Up 192.6% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Proprietary SNAP platform enabling rapid iterative molecular design and optimization
  • Selective FGFR inhibitor approach reducing off-target toxicity compared to pan-FGFR inhibitors
  • Diversified pipeline across multiple cancer indications and genetic disorders with high unmet medical needs
  • Focused development strategy targeting genetically defined patient populations with validated biomarkers
▼

Bear Case

1 risk

  • Low volatility (beta 0.8).

Growth

Revenue decline expected

Advancement of TYRA-300 through clinical development for muscle invasive bladder cancer treatment

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Falling

-25.8% over 3m

Quality

Loss-making

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Apr 30, 2026

“
Q2 26 RECAP

MAY 13, 2026

Reported EPS of -$0.64 vs -$0.60 consensus (-6.7% surprise).

EPS miss

EPS surprise · last 4Q

0 of 1 beats

Q2 26

-6.7%

Next: Apr 30, 2026

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

6 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

6

100%

Hold

0%

Sell

0%

Median Price Target

$54.00

▲ +77.9% vs $30.35

Low $54.00
Median $54.00
High $54.00

Latest: Bank of America · Jun 10, 2026

1 analyst covering

View full analyst page →

vs Industry

How TYRA stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.